Firefly Neuroscience CEO Jon Olsen to Present at H.C. Wainwright’s 26th Annual Global Investment Conference September 9-11
Firefly Neuroscience (NASDAQ: AIFF), an AI company focused on improving brain health outcomes, announced that CEO Jon Olsen will present at the H.C. Wainwright's 26th Annual Global Investment Conference on September 11, 2024, at 1:30 p.m. ET. The event will be held at the Lotte New York Palace Hotel.
Olsen will discuss recent corporate milestones, including the merger with WaveDancer and Firefly's FDA-510(k) cleared Brain Network Analytics (BNA™) platform. This innovative technology aims to support clinicians in diagnosing and optimizing patient care for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD.
Investors can schedule one-on-one meetings with Olsen and Chief Medical Officer Dr. Samer Kaba. A webcast of the presentation will be available, with a 90-day replay accessible on the company's website.
Firefly Neuroscience (NASDAQ: AIFF), un'azienda di intelligenza artificiale focalizzata sul miglioramento della salute cerebrale, ha annunciato che il CEO Jon Olsen presenterà alla 26ª Conferenza Globale Annuale sugli Investimenti di H.C. Wainwright il 11 settembre 2024, alle 13:30 ET. L'evento si terrà presso il Lotte New York Palace Hotel.
Olsen parlerà dei recenti traguardi aziendali, inclusa la fusione con WaveDancer e la piattaforma Brain Network Analytics (BNA™) di Firefly, approvata dalla FDA con il 510(k). Questa tecnologia innovativa mira a supportare i clinici nella diagnosi e nell'ottimizzazione della cura dei pazienti per condizioni come depressione, demenza, disturbi d'ansia, commozioni cerebrali e ADHD.
Gli investitori possono programmare incontri one-to-one con Olsen e il Chief Medical Officer Dr. Samer Kaba. Una registrazione della presentazione sarà disponibile, con una riproduzione accessibile sul sito web dell'azienda per 90 giorni.
Firefly Neuroscience (NASDAQ: AIFF), una empresa de inteligencia artificial centrada en mejorar los resultados de salud cerebral, anunció que el CEO Jon Olsen presentará en la 26ª Conferencia Global Anual de Inversión de H.C. Wainwright el 11 de septiembre de 2024, a la 1:30 p.m. ET. El evento se llevará a cabo en el Lotte New York Palace Hotel.
Olsen discutirá los hitos recientes de la compañía, incluida la fusión con WaveDancer y la plataforma Brain Network Analytics (BNA™) de Firefly, que ha sido liberada por la FDA bajo el 510(k). Esta innovadora tecnología tiene como objetivo apoyar a los clínicos en el diagnóstico y la optimización de la atención al paciente para condiciones como depresión, demencia, trastornos de ansiedad, conmociones cerebrales y TDAH.
Los inversores pueden programar reuniones individuales con Olsen y el Director Médico Dr. Samer Kaba. Se dispondrá de una transmisión en vivo de la presentación, con una repetición accesible en el sitio web de la empresa durante 90 días.
Firefly Neuroscience (NASDAQ: AIFF), 뇌 건강 결과 개선에 중점을 둔 인공지능 회사가 2024년 9월 11일 오후 1시 30분(ET)에 H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에서 CEO Jon Olsen이 발표할 것이라고 발표했습니다. 이 행사는 Lotte New York Palace Hotel에서 개최됩니다.
Olsen은 WaveDancer와의 합병 및 Firefly의 FDA 510(k) 승인을 받은 Brain Network Analytics (BNA™) 플랫폼을 포함한 최근 기업 이정표에 대해 논의할 것입니다. 이 혁신적인 기술은 임상의가 우울증, 치매, 불안 장애, 뇌진탕 및 ADHD와 같은 질환에 대한 진단 및 환자 치료 최적화를 지원하는 것을 목표로 합니다.
투자자는 Olsen과 Chief Medical Officer Dr. Samer Kaba와의 일대일 회의를 예약할 수 있습니다. 발표의 웹캐스트가 제공되며, 회사 웹사이트에서 90일간 다시 볼 수 있습니다.
Firefly Neuroscience (NASDAQ: AIFF), une entreprise d'intelligence artificielle axée sur l'amélioration des résultats en matière de santé cérébrale, a annoncé que le PDG Jon Olsen présentera à la 26ème Conférence Annuelle Mondiale d'Investissement de H.C. Wainwright le 11 septembre 2024 à 13h30 ET. L'événement se tiendra à l'Hôtel Lotte New York Palace.
Olsen discutera des récentes étapes clés de l'entreprise, y compris la fusion avec WaveDancer et la plateforme Brain Network Analytics (BNA™) de Firefly, approuvée par la FDA avec le 510(k). Cette technologie innovante vise à aider les cliniciens à diagnostiquer et à optimiser les soins aux patients pour des affections telles que la dépression, la démence, les troubles anxieux, les commotions cérébrales et le TDAH.
Les investisseurs peuvent planifier des réunions individuelles avec Olsen et le directeur médical, Dr. Samer Kaba. Une rediffusion de la présentation sera disponible, accessible sur le site Web de l'entreprise pendant 90 jours.
Firefly Neuroscience (NASDAQ: AIFF), ein KI-Unternehmen, das sich auf die Verbesserung der Gehirngesundheit konzentriert, gab bekannt, dass CEO Jon Olsen am 26. jährlichen Global Investment Conference von H.C. Wainwright am 11. September 2024 um 13:30 Uhr ET präsentieren wird. Die Veranstaltung findet im Lotte New York Palace Hotel statt.
Olsen wird über die jüngsten Fortschritte des Unternehmens sprechen, einschließlich der Fusion mit WaveDancer und der von der FDA genehmigten Brain Network Analytics (BNA™)-Plattform von Firefly. Diese innovative Technologie soll Fachleuten helfen, Diagnosen zu stellen und die Patientenversorgung bei Arbeiten wie Depressionen, Demenz, Angststörungen, Gehirnerschütterungen und ADHD zu optimieren.
Investoren können Einzelgespräche mit Olsen und dem Chief Medical Officer Dr. Samer Kaba vereinbaren. Eine Webcast der Präsentation wird verfügbar sein, mit einer 90-tägigen Wiederholung auf der Website des Unternehmens.
- None.
- None.
TORONTO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced that its Chief Executive Officer, Jon Olsen, will present at H.C. Wainwright’s 26th Annual Global Investment Conference being held at the Lotte New York Palace Hotel in New York City on September 9-11, 2024.
Mr. Olsen will discuss recent corporate milestones, including closing the merger transaction with WaveDancer and Firefly’s FDA-510(k) cleared Brain Network Analytics (BNA™) platform. The Company is dedicated to improving outcomes for people suffering with brain health illnesses by bringing objective measurement of brain activity to the front lines of healthcare. The Company believes that BNA™ can help support clinicians in the diagnosis and optimization of patient care for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD.
H.C. Wainwright 26th Annual Global Investment Conference
Date: Wednesday, September 11, 2024
Time: 1:30 p.m. ET
Location: Lotte New York Palace Hotel, New York
Speaker: Jon Olsen, CEO
Webcast: https://journey.ct.events/view/099c5b86-c887-4a29-b256-3a2565c927e0
To schedule a one-on-one investor meeting with Mr. Olsen and Dr. Samer Kaba, the Company’s Chief Medical Officer, please contact your H.C. Wainwright representative or KCSA Strategic Communications at Firefly@KCSA.com.
A replay of this presentation will be available for 90 days following the date of the presentation on the Company’s website at https://investors.fireflyneuro.com/events-presentations.
About Firefly
Firefly (Nasdaq: AIFF) is an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Firefly’s FDA-510(k) cleared Brain Network Analytics (BNA™) technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has built a comprehensive database of brain wave tests, securing patent protection, and achieving FDA clearance. The Company is now launching BNA™ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use.
Brain Network Analytics was developed using artificial intelligence and machine learning on Firefly’s extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) of over 17,000 patients representing twelve disorders, as well as clinically normal patients. BNA™, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function. These insights can enhance a clinician’s ability to accurately diagnose mental and cognitive disorders and to evaluate what therapy and/or drug is best suited to optimize a patient’s outcome.
Please visit https://fireflyneuro.com/ for more information.
Forward-Looking Statements
Certain statements in this press release and the information incorporated herein by reference may constitute “forward-looking statements” for purposes of the federal securities laws concerning Firefly. These forward-looking statements include express or implied statements relating to Firefly’s management teams’ expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to development and commercialization of BNA technology; risks related to Firefly’s ability to recognize the anticipated benefits of the merger (the “Merger”) with WaveDancer, Inc. (“WaveDancer”); risks related to Firefly’s ability to correctly estimate its operating expenses and expenses associated with the Merger and other events and unanticipated spending and costs that could reduce Firefly’s cash resources; the ability of Firefly to protect its intellectual property rights; competitive responses to the business combination; unexpected costs, charges or expenses resulting from the Merger; potential adverse reactions or changes to business relationships resulting from the completion of the Merger; legislative, regulatory, political and economic developments; and those factors described under the heading “Risk Factors” in the in the registration statement on Form S-4 filed by WaveDancer with the Securities and Exchange Commission on January 22, 2024, as amended, and declared effective on February 6, 2024. Should one or more of these risks or uncertainties materialize, or should any of Firefly’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Investor Contact
KCSA Strategic Communications
Valter Pinto, Managing Director
(212) 896-1254
Firefly@KCSA.com
Media Contact
KCSA Strategic Communications
Raquel Cona, Vice President
(516) 779-2630
Rcona@KCSA.com
FAQ
When and where is Firefly Neuroscience presenting at the H.C. Wainwright conference?
What will Firefly Neuroscience CEO Jon Olsen discuss in his presentation?
How can investors access the Firefly Neuroscience presentation at the H.C. Wainwright conference?
What is the main focus of Firefly Neuroscience's BNA™ platform?
